Cellectis S.A.

Developing allogeneic CAR T-cell cancer immunotherapies using TALEN® gene-editing technology.

CLLS | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 8 RUE DE LA CROIX JARRY, 0 PARIS, LLE-DE-FRANCE
Website:: https://www.cellectis.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in the development of cancer immunotherapies. The company leverages its proprietary gene-editing technology, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Cellectis focuses on creating allogeneic, or "off-the-shelf," CAR T-cell product candidates from healthy donor cells. This approach aims to provide broadly available and scalable treatments for a large number of patients, in contrast to personalized autologous therapies. The company's technology is designed to solve key challenges in allogeneic cell therapy, including Graft-versus-Host Disease (GvHD) and host-versus-graft rejection. Cellectis maintains a strong intellectual property portfolio and collaborates with global strategic partners to advance its therapeutic pipeline.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cellectis S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellectis S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Cellectis S.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Disc Medicine, Inc. Developing novel therapies for patients with serious hematologic and rare blood disorders.	United States of America	IRON
DONG-A ST CO.,LTD Develops and distributes ethical drugs, medical devices, and diagnostics for global healthcare.	South Korea	170900
DongKoo Bio & Pharma Co., Ltd. Pharma leader in dermatology, developing treatments, probiotics, and investing in biotech therapies.	South Korea	006620
DongKook Life Science Co., Ltd. A pharmaceutical firm specializing in contrast media for diagnostic imaging and medical devices.	South Korea	303810
DongKookPharmaceuticalCo.,Ltd. Develops, manufactures, and distributes pharmaceuticals and healthcare products globally.	South Korea	086450
DONGSUNG PHARMACEUTICAL CO.,LTD A Korean firm making pharmaceuticals, cosmetics, and popular hair care products for over 60 years.	South Korea	002210
DONGWHA PHARM.CO.,LTD Develops, manufactures, and sells a diverse portfolio of healthcare products globally.	South Korea	000020
Dottikon ES Holding AG Exclusive synthesis of APIs & fine chemicals via hazardous reactions for pharma/biotech industries.	Switzerland	DESN
Double Bond Pharmaceutical International AB Redeveloping drugs with proprietary delivery tech for oncology & infectious diseases.	Sweden	DBP B
DR REDDYS LABORATORIES LTD Global pharma firm providing affordable generics, APIs, and medicines to patients worldwide.	United States of America	RDY